Hematologic Oncology | Specialty

Dr. Farhad Ravandi Discusses Vosaroxin in the VALOR Trial

December 7th 2014

Farhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center in Houston, describes results from the phase III VALOR trial that explored vosaroxin plus cytarabine versus placebo and cytarabine in patients with first relapsed or refractory acute myeloid leukemia.

Dr. Eytan Stein Discusses the IDH2 Inhibitor AG-221 in AML

December 7th 2014

Eytan Stein, MD, from the Memorial Sloan Kettering Cancer Center, discusses new data from a phase I study exploring the oral IDH2 inhibitor AG-221 in patients with advanced hematologic malignancies, primarily acute myelogenous leukemia and myelodysplastic syndrome.

Blinatumomab Leads to High MRD Response in B-Precursor ALL

December 7th 2014

At least 80% of patients with B-precursor acute lymphoblastic leukemia had a complete minimal residual disease response after a single cycle of treatment with the CD19-directed antibody blinatumomab.

Dr. Grupp on Optimal Treatment Settings for CAR-Modified T Cells

December 6th 2014

Stephan Grupp, MD, PhD, of the Children's Hospital of Philadelphia, discusses the optimal treatment settings for novel CD19-specific CAR-modified T cell therapies in patients with acute lymphoblastic leukemia.

FDA Approves Ruxolitinib for Polycythemia Vera

December 4th 2014

The FDA has approved the JAK1/2 inhibitor ruxolitinib as treatment for patients with polycythemia vera who are resistant or intolerant to hydroxyurea

FDA Approves Blinatumomab for Acute Lymphoblastic Leukemia

December 3rd 2014

The FDA has approved the bispecific T cell engager antibody blinatumomab as a treatment for adult patients with Philadelphia chromosome-negative relapsed/refractory B-precursor acute lymphoblastic leukemia.

ASH 2014 Preview: Checkpoint Inhibition, CAR Modified T Cells, and Novel Therapies

December 1st 2014

The top research being presented at the 2014 American Society of Hematology Annual Meeting will focus on immunotherapies and novel agents, according to Marcel R.M. van den Brink, MD, PhD.

Dr. van den Brink Highlights Five Abstracts From ASH 2014

December 1st 2014

Marcel R.M. van den Brink, MD, PhD, Head, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, provides an overview of five notable studies being presented at the 2014 American Society of Hematology (ASH) Meeting and Exposition.

Latest News & Insight: November 26, 2014

November 27th 2014

CURE Magazine and Incyte to Honor MPN Heroes

November 27th 2014

Award reception and gala will recognize the work and achievements of individuals dedicated to improving the lives of people living with rare blood disorders

Anderson Provides Insight Into Novel Agents in Multiple Myeloma

November 26th 2014

The treatment of patients with multiple myeloma is poised to undergo a dramatic transformation, as novel monoclonal antibodies and combination strategies race toward approval.

FDA Extends Panobinostat Review Period for Multiple Myeloma

November 25th 2014

The FDA has extended the review period for panobinostat (LBH589) in combination with bortezomib (Velcade) and dexamethasone for patients with previously treated multiple myeloma by 3 months, placing a new decision date in early 2015.

Juno CAR T Cell Therapy Receives Breakthrough Designation for ALL

November 24th 2014

The chimeric antigen receptor (CAR) T cell therapy JCAR015 has received a breakthrough therapy designation from the FDA as a treatment for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).

Dr. Brody Discusses Exciting Therapies for Lymphomas and CLL

November 24th 2014

Joshua Brody, MD, assistant professor, Icahn School of Medicine, director, Lymphoma Immunotherapy Program, Mount Sinai Hospital, discusses exciting new therapies for lymphomas and chronic lymphocytic leukemia (CLL).

FDA Grants Orphan Drug Designation to BGB324 for AML

November 24th 2014

The FDA has granted an orphan drug designation to the novel AXL inhibitor BGB324 (R428) for the treatment of patients with acute myeloid leukemia (AML).

Early IDH1 Inhibitor Data Promising in AML

November 24th 2014

The IDH1 inhibitor AG-120 has shown a favorable safety and efficacy profile in patients with IDH1 mutation positive advanced hematologic malignancies, including acute myeloid leukemia (AML).

Juno Files for IPO as CAR Therapies Continue to Advance

November 19th 2014

Juno Therapeutics, Inc, has filed a registration statement for an initial public offering of its common stock, as its early stage therapies continue to advance in clinical trials.

Bringing CARs to Market: Novel T-Cell Therapies Make Rapid Progress Despite Challenges

November 18th 2014

When Marcela V. Maus, MD, PhD, thinks of the challenge of bringing chimeric antigen receptor (CAR) therapies to market in the battle against cancer, she is reminded of the auto industry's first days.

Treatments for Follicular Lymphoma Continue to Evolve

November 13th 2014

A growing understanding of follicular lymphoma pathogenesis is resulting in new drug candidates and approaches to clinical treatment.

Dr. Goy Discusses Intensive Therapy for MCL

November 12th 2014

Andre Goy, MD, MS, discusses intensive therapy for the treatment of patients with mantle cell lymphoma (MCL).